Scientists test new Cancer-Fighting duo in early safety trial
NCT ID NCT03239145
Summary
This early-stage study tested the safety of combining two drugs, pembrolizumab and AMG386, in 62 patients with advanced solid tumors like melanoma, ovarian, kidney, or colorectal cancer. The goal was to see if the combination was safe and to find the right dose, as lab research suggested the drugs might work better together. The study also looked for early signs that the treatment could help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.